UBS Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.7
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Doug Schenkel maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $3.05 to $2.7.
UBS analyst Doug Schenkel maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $3.05 to $2.7.